KNSA FY 2020 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$4M

Operating Income

-$157M

Net Income

-$161M

EPS (Diluted)

$-2.61

Cash Flow

Operating Cash Flow

-$137M

Free Cash Flow

-$137M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$349M

Total Liabilities

$38M

Stockholders' Equity

$312M

Cash & Equivalents

$114M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$4M	-$3M	-16.0%
Operating Income	-$157M	-$170M	+7.4%
Net Income	-$161M	-$162M	+0.3%